|Detection of circulating tumor DNA in early-and late-stage human malignancies|
C Bettegowda, M Sausen, RJ Leary, I Kinde, Y Wang, N Agrawal, ...
Science translational medicine 6 (224), 224ra24-224ra24, 2014
|Survival, durable tumor remission, and long-term safety in patients with advanced melanoma receiving nivolumab|
SL Topalian, M Sznol, DF McDermott, HM Kluger, RD Carvajal, ...
Journal of clinical oncology 32 (10), 1020, 2014
|PD-1 blockade with pembrolizumab in advanced Merkel-cell carcinoma|
PT Nghiem, S Bhatia, EJ Lipson, RR Kudchadkar, NJ Miller, L Annamalai, ...
New England Journal of Medicine 374 (26), 2542-2552, 2016
|Durable cancer regression off-treatment and effective reinduction therapy with an anti-PD-1 antibody|
EJ Lipson, WH Sharfman, CG Drake, I Wollner, JM Taube, RA Anders, ...
Clinical Cancer Research 19 (2), 462-468, 2013
|Evolutionary dynamics of cancer in response to targeted combination therapy|
I Bozic, JG Reiter, B Allen, T Antal, K Chatterjee, P Shah, YS Moon, ...
elife 2, e00747, 2013
|Breathing new life into immunotherapy: review of melanoma, lung and kidney cancer|
CG Drake, EJ Lipson, JR Brahmer
Nature reviews Clinical oncology 11 (1), 24, 2014
|Ipilimumab: an anti-CTLA-4 antibody for metastatic melanoma|
EJ Lipson, CG Drake
Clinical cancer research 17 (22), 6958-6962, 2011
|PD-L1 expression in the Merkel cell carcinoma microenvironment: association with inflammation, Merkel cell polyomavirus, and overall survival|
EJ Lipson, JG Vincent, M Loyo, LT Kagohara, BS Luber, H Wang, H Xu, ...
Cancer immunology research 1 (1), 54-63, 2013
|Cardiotoxicity associated with CTLA4 and PD1 blocking immunotherapy|
L Heinzerling, PA Ott, FS Hodi, AN Husain, A Tajmir-Riahi, H Tawbi, ...
Journal for immunotherapy of cancer 4 (1), 50, 2016
|Clinicopathological features of acute kidney injury associated with immune checkpoint inhibitors|
FB Cortazar, KA Marrone, ML Troxell, KM Ralto, MP Hoenig, JR Brahmer, ...
Kidney international 90 (3), 638-647, 2016
|Inflammatory arthritis and sicca syndrome induced by nivolumab and ipilimumab|
LC Cappelli, AK Gutierrez, AN Baer, J Albayda, RL Manno, U Haque, ...
Annals of the rheumatic diseases 76 (1), 43-50, 2017
|Antagonists of PD-1 and PD-L1 in cancer treatment|
EJ Lipson, PM Forde, HJ Hammers, LA Emens, JM Taube, SL Topalian
Seminars in oncology 42 (4), 587-600, 2015
|Tumor regression and allograft rejection after administration of anti–PD-1|
EJ Lipson, SM Bagnasco, J Moore Jr, S Jang, MJ Patel, AA Zachary, ...
The New England journal of medicine 374 (9), 896, 2016
|Association of autoimmune encephalitis with combined immune checkpoint inhibitor treatment for metastatic cancer|
TJ Williams, DR Benavides, KA Patrice, JO Dalmau, ALR De Ávila, DT Le, ...
JAMA neurology 73 (8), 928-933, 2016
|Circulating tumor DNA analysis as a real-time method for monitoring tumor burden in melanoma patients undergoing treatment with immune checkpoint blockade|
EJ Lipson, VE Velculescu, TS Pritchard, M Sausen, DM Pardoll, ...
Journal for immunotherapy of cancer 2 (1), 42, 2014
|Nivolumab: targeting PD-1 to bolster antitumor immunity|
JR Brahmer, H Hammers, EJ Lipson
Future oncology 11 (9), 1307-1326, 2015
|Initial efficacy of anti-lymphocyte activation gene-3 (anti–LAG-3; BMS-986016) in combination with nivolumab (nivo) in pts with melanoma (MEL) previously treated with anti–PD-1 …|
PA Ascierto, I Melero, S Bhatia, P Bono, RE Sanborn, EJ Lipson, ...
Journal of Clinical Oncology 35 (15_suppl), 9520-9520, 2017
|Long-term survival of ipilimumab-naive patients (pts) with advanced melanoma (MEL) treated with nivolumab (anti-PD-1, BMS-936558, ONO-4538) in a phase I trial.|
FS Hodi, M Sznol, HM Kluger, DF McDermott, RD Carvajal, DP Lawrence, ...
Journal of Clinical Oncology 32 (15_suppl), 9002-9002, 2014
|Concurrent immune checkpoint inhibitors and stereotactic radiosurgery for brain metastases in non-small cell lung cancer, melanoma, and renal cell carcinoma|
L Chen, J Douglass, L Kleinberg, X Ye, AE Marciscano, PM Forde, ...
International Journal of Radiation Oncology* Biology* Physics 100 (4), 916-925, 2018
|Myeloid-derived suppressor cell subset accumulation in renal cell carcinoma parenchyma is associated with intratumoral expression of IL1β, IL8, CXCL5, and Mip-1α|
YG Najjar, P Rayman, X Jia, PG Pavicic, BI Rini, C Tannenbaum, J Ko, ...
Clinical Cancer Research 23 (9), 2346-2355, 2017